About Tessa Therapeutics
Tessa Therapeutics is a clinical-stage immunotherapy company focused on the development of autologous and off-the-shelf, allogeneic therapies for cancer patients.
Our Virus-Specific T cell (VST) platform harnesses the body’s potent anti-viral immune response and has shown compelling results in the treatment of solid tumors.
We are building a portfolio of innovative, next-generation therapies which combine the qualities of VSTs with other immuno-oncology technologies.
Our robust operational and supply chain capabilities enable us to successfully deliver T cell therapy treatments to a large patient pool worldwide. Together with our academic, clinical, and commercial research partners, we have created a fully-integrated approach to the treatment of cancer with immunotherapy.
The immunosuppressive tumor microenvironment presents significant obstacles to the treatment of solid tumors with immunotherapy. Our Virus-Specific T cell (VST) technology overcomes these barriers and has shown promising clinical success.
We have a rapidly growing pipeline of autologous and allogenic therapies targeting multiple cancer indications. These innovative, next-generation therapies combine the qualities of VSTs with other immuno-oncology technologies.
We are committed to working towards a vision of a world without untreatable cancers. We are constantly advancing our understanding of the body’s immune system to design next-generation VST therapies which demonstrate persistence, durability, and tumor penetration with minimal side effects for patients.
Tessa on Twitter
We were excited to have had presented four posters at the Keystone #Cancerimmunotherapy Symposium highlighting #VSTs as a platform for CART-T therapies and other immuno-oncology technologies in targeting solid tumors. #KScancerimm #Immunotherapy #CARTcell #celltherapy https://t.co/mkQEPbVYn7
Tessa’s Media Channel
CNBC Anchor, Nancy Hungerford speaks with Tessa’s CFO, Desmond Lim about the Company’s future plans and the promise of Virus-Specific T Cell (VST) cancer immunotherapy.